Tricuspid annular plane systolic excursion (TAPSE) measured by echocardiography and mortality in COVID-19: A systematic review and meta-analysis

• Published in: International journal of infectious diseases Vol. 105; pp. 351 - 356
• Main Authors: Martha, Januar Wibawa, Pranata, Raymond, Wibowo, Arief, Lim, Michael Anthonius
• Format: Journal Article
• Language: English
• Published: Canada Elsevier Ltd 01-04-2021; The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases; Elsevier
• Subjects: Cardiovascular; Critical care; Echocardiography; Prognosis; TAPSE; Critical care; Echocardiography; Prognosis; TAPSE; Cardiovascular
• ISSN: 1201-9712; 1878-3511
• DOI: 10.1016/j.ijid.2021.02.029

•TAPSE lower in COVID-19 non-survivors compared with survivors.•Meta-regression showed that differences in TAPSE decreased by COPD and PASP.•Each 1 mm decrease in TAPSE associated with mortality increase of approximately 20%.
In this systematic review and meta-analysis, we assessed the association between tricuspid annular plane systolic excursion (TAPSE) measured by echocardiography and mortality in coronavirus disease 2019 (COVID-19).
We performed a systematic literature search using PubMed, Embase, and Scopus databases with the keywords “COVID-19” OR “SARS-CoV-2” OR “2019-nCoV” AND “Tricuspid annular plane systolic excursion” OR “TAPSE” until January 20, 2021. The main outcome was mortality. The effect estimate was reported as the hazard ratio (HR), which was pooled from the unadjusted and adjusted effect estimates retrieved from the studies included. Mean differences in TAPSE (in mm) between non-survivors and survivors were pooled.
In total, 641 patients from seven studies were included in this systematic review and meta-analysis. TAPSE was lower in non-survivors compared with survivors (mean difference = –3.74 [–5.22, –2.26], p < 0.001; I2: 85.5%, p < 0.001). Each 1 mm decrease in TAPSE was associated with increased mortality (HR = 1.24 [1.18, 1.31], p < 0.001; I2: 0.0%, p = 0.491). In the pooled adjusted model, each 1 mm decrease in TAPSE was associated with increased mortality (HR = 1.21 [1.11, 1.33], p < 0.001; I2: 45.1%, p = 0.156). Meta-regression indicated that the difference in TAPSE between non-survivors and survivors was affected by chronic obstructive pulmonary disease (–0.183, p < 0.001) and pulmonary artery systolic pressure (–0.344, p = 0.039), but not by age (p = 0.668), male gender (p = 0.821), hypertension (p = 0.101), diabetes (p = 0.603), coronary artery disease (p = 0.564), smoking (p = 0.140), and left ventricular ejection fraction (p = 0.452).
Every 1 mm decrease in TAPSE was associated with an increase in mortality of approximately 20%.
CRD42021232194